Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
555 participants
INTERVENTIONAL
2004-07-31
2006-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
GALLANT 9 Tesaglitazar vs. Placebo in Combination With Insulin
NCT00242372
GALLANT 5 Tesaglitazar Versus Metformin
NCT00214591
GALLANT 4 Tesaglitazar vs. Glibenclamide
NCT00255541
GALLANT 7 Tesaglitazar Add-on to Sulphonylurea
NCT00251940
GALLANT 2 Tesaglitazar vs. Placebo
NCT00252772
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tesaglitazar
Metformin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Men or women who are \>=18 years of age
* Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
* Diagnosed with type 2 diabetes
* Treated with diet alone or treatment with a single oral antidiabetic agent or low doses of two oral antidiabetic agents
Exclusion Criteria
* New York Heart Association heart failure Class III or IV
* Treatment with chronic insulin
* History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
* History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
* Creatinine levels above twice the normal range
* Creatine kinase above 3 times the upper limit of normal
* Received any investigational product in other clinical studies within 12 weeks
* Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AstraZeneca
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
AstraZeneca Galida Medical Science Director, MD
Role: STUDY_DIRECTOR
AstraZeneca
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Research Site
Adelaide, , Australia
Research Site
Brisbane, , Australia
Research Site
Cairns, , Australia
Research Site
Geelong, , Australia
Research Site
Melbourne, , Australia
Research Site
Perth, , Australia
Research Site
Sydney, , Australia
Research Site
Coquitlam, British Columbia, Canada
Research Site
Winnipeg, Manitoba, Canada
Research Site
St. John's, Newfoundland and Labrador, Canada
Research Site
Etobicoke, Ontario, Canada
Research Site
Hamilton, Ontario, Canada
Research Site
Hastings, Ontario, Canada
Research Site
Kingston, Ontario, Canada
Research Site
North York, Ontario, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Smith Falls, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Chomedey-Laval, Quebec, Canada
Research Site
Laval, Quebec, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Hämeenlinna, , Finland
Research Site
Helsinki, , Finland
Research Site
Joensuu, , Finland
Research Site
Kouvola, , Finland
Research Site
Kuopio, , Finland
Research Site
Mikkeli, , Finland
Research Site
Oulu, , Finland
Research Site
Salo, , Finland
Research Site
Tampere, , Finland
Research Site
Vantaa, , Finland
Research Site
Aschaffenburg, , Germany
Research Site
Berlin, , Germany
Research Site
Essen, , Germany
Research Site
Hamburg, , Germany
Research Site
Heidelberg, , Germany
Research Site
Mannheim, , Germany
Research Site
Nürberg, , Germany
Research Site
Rotenburg/Fulda, , Germany
Research Site
Bangalore, , India
Research Site
Hyderabad, , India
Research Site
New Delhi, , India
Research Site
Arenzano, , Italy
Research Site
Chiavari (GE), , Italy
Research Site
Chieri, , Italy
Research Site
Desio, , Italy
Research Site
Florence, , Italy
Research Site
Gubbio, , Italy
Research Site
Marsala, , Italy
Research Site
Messina, , Italy
Research Site
Milan, , Italy
Research Site
Monteccio Emilia, , Italy
Research Site
Napoli, , Italy
Research Site
Padua, , Italy
Research Site
Perugia, , Italy
Research Site
Pescara, , Italy
Research Site
Piacenza, , Italy
Research Site
Pistoia, , Italy
Research Site
Reggio Calabria, , Italy
Research Site
Reggio Emilia, , Italy
Research Site
Rho, , Italy
Research Site
Roma, , Italy
Research Site
Scandiano, , Italy
Research Site
Udine, , Italy
Research Site
Kubang Kerian, Kota Bharu, Malaysia
Research Site
Kuala Lumpur, , Malaysia
Research Site
Cebu City, , Philippines
Research Site
Quezon City, , Philippines
Research Site
Singapore, , Singapore
Research Site
Ängelholm, , Sweden
Research Site
Borås, , Sweden
Research Site
Dalby, , Sweden
Research Site
Gothenburg, , Sweden
Research Site
Höganäs, , Sweden
Research Site
Kungsör, , Sweden
Research Site
Malmo, , Sweden
Research Site
Mölndal, , Sweden
Research Site
Oskarshamn, , Sweden
Research Site
Skene, , Sweden
Research Site
Skrivarp, , Sweden
Research Site
Stenungsund, , Sweden
Research Site
Uppsala, , Sweden
Research Site
Aberdeen, , United Kingdom
Research Site
Aldershot, , United Kingdom
Research Site
Atherstone, , United Kingdom
Research Site
Barry, , United Kingdom
Research Site
Bath, , United Kingdom
Research Site
Bexhill-on-Sea, , United Kingdom
Research Site
Birmingham, , United Kingdom
Research Site
Bolton, , United Kingdom
Research Site
Cardiff, , United Kingdom
Research Site
Chippenham, , United Kingdom
Research Site
Coventry, , United Kingdom
Research Site
Dundee, , United Kingdom
Research Site
Edinburgh, , United Kingdom
Research Site
Glasgow, , United Kingdom
Research Site
Harrow, , United Kingdom
Research Site
Hastings, , United Kingdom
Research Site
Leeds, , United Kingdom
Research Site
Liverpool, , United Kingdom
Research Site
Manchester, , United Kingdom
Research Site
Plymouth, , United Kingdom
Research Site
Radstock, , United Kingdom
Research Site
Slough, , United Kingdom
Research Site
Swindon, , United Kingdom
Research Site
West Midlands, , United Kingdom
Research Site
Wrexham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EudraCT No 2004-000348-25
Identifier Type: -
Identifier Source: secondary_id
D6160C00031
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.